Selected research
Market Structure
Global mRNA Vaccines for Infectious Diseases Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global mRNA Vaccines for Infectious Diseases market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for mRNA Vaccines for Infectious Diseases is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of mRNA Vaccines for Infectious Diseases include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global mRNA Vaccines for Infectious Diseases market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of mRNA Vaccines for Infectious Diseases and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents mRNA Vaccines for Infectious Diseases revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the mRNA Vaccines for Infectious Diseases market size, projected growth trends, production technologies, key applications, and end-use industries.
mRNA Vaccines for Infectious Diseases Segment by Company
Translate Bio
Tiba Biotechnology
Sangamo Therapeutics
Moderna Therapeutics
In-Cell-Art
Ethris
eTheRNA
CureVac
BioNTech
Argos Therapeutics
mRNA Vaccines for Infectious Diseases Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines for Infectious Diseases Segment by Application
Infectious Disease
Cancer
mRNA Vaccines for Infectious Diseases Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines for Infectious Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines for Infectious Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines for Infectious Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of mRNA Vaccines for Infectious Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccines for Infectious Diseases industry.
Chapter 3: Detailed analysis of mRNA Vaccines for Infectious Diseases companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Vaccines for Infectious Diseasesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Infectious Disease Vaccines
- Cancer Vaccines
Applications
- Infectious Disease
- Cancer
Companies covered
- Translate Bio
- Tiba Biotechnology
- Sangamo Therapeutics
- Moderna Therapeutics
- In-Cell-Art
- Ethris
- eTheRNA
- CureVac
- BioNTech
- Argos Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Infectious Disease Vaccines
- 1.2.3 Cancer Vaccines
- 1.3 Market Analysis by Application
- 1.3.1 Global mRNA Vaccines for Infectious Diseases Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Infectious Disease
- 1.3.3 Cancer
- 1.4 Global Market Growth Prospects
- 1.5 Global mRNA Vaccines for Infectious Diseases Growth Trends by Region
- 1.5.1 Global mRNA Vaccines for Infectious Diseases Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 mRNA Vaccines for Infectious Diseases Market Size by Region (2021-2026)
- 1.5.3 mRNA Vaccines for Infectious Diseases Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global mRNA Vaccines for Infectious Diseases Market Dynamics
- 2.1 mRNA Vaccines for Infectious Diseases Industry Trends
- 2.2 mRNA Vaccines for Infectious Diseases Industry Drivers
- 2.3 mRNA Vaccines for Infectious Diseases Industry Opportunities and Challenges
- 2.4 mRNA Vaccines for Infectious Diseases Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global mRNA Vaccines for Infectious Diseases Revenue by Company (2021-2026)
- 3.2 Global mRNA Vaccines for Infectious Diseases Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global mRNA Vaccines for Infectious Diseases Key Company Head office and Area Served
- 3.4 Global mRNA Vaccines for Infectious Diseases Company, Product Type & Application
- 3.5 Global mRNA Vaccines for Infectious Diseases Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global mRNA Vaccines for Infectious Diseases Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 mRNA Vaccines for Infectious Diseases Players Market Share by Revenue in 2025
- 3.6.3 2025 mRNA Vaccines for Infectious Diseases Tier 1, Tier 2, and Tier 3
4 mRNA Vaccines for Infectious Diseases Market by Type
- 4.1 Global mRNA Vaccines for Infectious Diseases Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global mRNA Vaccines for Infectious Diseases Market Size by Type (2021-2032)
- 4.3 Global mRNA Vaccines for Infectious Diseases Market Size Share by Type (2021-2032)
5 mRNA Vaccines for Infectious Diseases Market by Application
- 5.1 Global mRNA Vaccines for Infectious Diseases Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global mRNA Vaccines for Infectious Diseases Market Size by Application (2021-2032)
- 5.3 Global mRNA Vaccines for Infectious Diseases Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Translate Bio
- 6.1.1 Translate Bio Company Information
- 6.1.2 Translate Bio Business Overview
- 6.1.3 Translate Bio mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Translate Bio mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.1.5 Translate Bio Recent Developments
- 6.2 Tiba Biotechnology
- 6.2.1 Tiba Biotechnology Company Information
- 6.2.2 Tiba Biotechnology Business Overview
- 6.2.3 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.2.5 Tiba Biotechnology Recent Developments
- 6.3 Sangamo Therapeutics
- 6.3.1 Sangamo Therapeutics Company Information
- 6.3.2 Sangamo Therapeutics Business Overview
- 6.3.3 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.3.5 Sangamo Therapeutics Recent Developments
- 6.4 Moderna Therapeutics
- 6.4.1 Moderna Therapeutics Company Information
- 6.4.2 Moderna Therapeutics Business Overview
- 6.4.3 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.4.5 Moderna Therapeutics Recent Developments
- 6.5 In-Cell-Art
- 6.5.1 In-Cell-Art Company Information
- 6.5.2 In-Cell-Art Business Overview
- 6.5.3 In-Cell-Art mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 In-Cell-Art mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.5.5 In-Cell-Art Recent Developments
- 6.6 Ethris
- 6.6.1 Ethris Company Information
- 6.6.2 Ethris Business Overview
- 6.6.3 Ethris mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Ethris mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.6.5 Ethris Recent Developments
- 6.7 eTheRNA
- 6.7.1 eTheRNA Company Information
- 6.7.2 eTheRNA Business Overview
- 6.7.3 eTheRNA mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 eTheRNA mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.7.5 eTheRNA Recent Developments
- 6.8 CureVac
- 6.8.1 CureVac Company Information
- 6.8.2 CureVac Business Overview
- 6.8.3 CureVac mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 CureVac mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.8.5 CureVac Recent Developments
- 6.9 BioNTech
- 6.9.1 BioNTech Company Information
- 6.9.2 BioNTech Business Overview
- 6.9.3 BioNTech mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 BioNTech mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.9.5 BioNTech Recent Developments
- 6.10 Argos Therapeutics
- 6.10.1 Argos Therapeutics Company Information
- 6.10.2 Argos Therapeutics Business Overview
- 6.10.3 Argos Therapeutics mRNA Vaccines for Infectious Diseases Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Argos Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
- 6.10.5 Argos Therapeutics Recent Developments
7 North America
- 7.1 North America mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 7.2 North America mRNA Vaccines for Infectious Diseases Market Size by Type
- 7.2.1 North America mRNA Vaccines for Infectious Diseases Market Size by Type (2021-2026)
- 7.2.2 North America mRNA Vaccines for Infectious Diseases Market Size by Type (2027-2032)
- 7.2.3 North America mRNA Vaccines for Infectious Diseases Market Share by Type (2021-2032)
- 7.3 North America mRNA Vaccines for Infectious Diseases Market Size by Application
- 7.3.1 North America mRNA Vaccines for Infectious Diseases Market Size by Application (2021-2026)
- 7.3.2 North America mRNA Vaccines for Infectious Diseases Market Size by Application (2027-2032)
- 7.3.3 North America mRNA Vaccines for Infectious Diseases Market Share by Application (2021-2032)
- 7.4 North America mRNA Vaccines for Infectious Diseases Market Size by Country
- 7.4.1 North America mRNA Vaccines for Infectious Diseases Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 7.4.3 North America mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 7.4.4 North America mRNA Vaccines for Infectious Diseases Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 8.2 Europe mRNA Vaccines for Infectious Diseases Market Size by Type
- 8.2.1 Europe mRNA Vaccines for Infectious Diseases Market Size by Type (2021-2026)
- 8.2.2 Europe mRNA Vaccines for Infectious Diseases Market Size by Type (2027-2032)
- 8.2.3 Europe mRNA Vaccines for Infectious Diseases Market Share by Type (2021-2032)
- 8.3 Europe mRNA Vaccines for Infectious Diseases Market Size by Application
- 8.3.1 Europe mRNA Vaccines for Infectious Diseases Market Size by Application (2021-2026)
- 8.3.2 Europe mRNA Vaccines for Infectious Diseases Market Size by Application (2027-2032)
- 8.3.3 Europe mRNA Vaccines for Infectious Diseases Market Share by Application (2021-2032)
- 8.4 Europe mRNA Vaccines for Infectious Diseases Market Size by Country
- 8.4.1 Europe mRNA Vaccines for Infectious Diseases Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 8.4.3 Europe mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 8.4.4 Europe mRNA Vaccines for Infectious Diseases Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 9.2 China mRNA Vaccines for Infectious Diseases Market Size by Type
- 9.2.1 China mRNA Vaccines for Infectious Diseases Market Size by Type (2021-2026)
- 9.2.2 China mRNA Vaccines for Infectious Diseases Market Size by Type (2027-2032)
- 9.2.3 China mRNA Vaccines for Infectious Diseases Market Share by Type (2021-2032)
- 9.3 China mRNA Vaccines for Infectious Diseases Market Size by Application
- 9.3.1 China mRNA Vaccines for Infectious Diseases Market Size by Application (2021-2026)
- 9.3.2 China mRNA Vaccines for Infectious Diseases Market Size by Application (2027-2032)
- 9.3.3 China mRNA Vaccines for Infectious Diseases Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 10.2 Asia mRNA Vaccines for Infectious Diseases Market Size by Type
- 10.2.1 Asia mRNA Vaccines for Infectious Diseases Market Size by Type (2021-2026)
- 10.2.2 Asia mRNA Vaccines for Infectious Diseases Market Size by Type (2027-2032)
- 10.2.3 Asia mRNA Vaccines for Infectious Diseases Market Share by Type (2021-2032)
- 10.3 Asia mRNA Vaccines for Infectious Diseases Market Size by Application
- 10.3.1 Asia mRNA Vaccines for Infectious Diseases Market Size by Application (2021-2026)
- 10.3.2 Asia mRNA Vaccines for Infectious Diseases Market Size by Application (2027-2032)
- 10.3.3 Asia mRNA Vaccines for Infectious Diseases Market Share by Application (2021-2032)
- 10.4 Asia mRNA Vaccines for Infectious Diseases Market Size by Country
- 10.4.1 Asia mRNA Vaccines for Infectious Diseases Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 10.4.3 Asia mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 10.4.4 Asia mRNA Vaccines for Infectious Diseases Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 11.2 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Type
- 11.2.1 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Application
- 11.3.1 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Country
- 11.4.1 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa mRNA Vaccines for Infectious Diseases Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst